Company Overview of Sandoz International GmbH
Sandoz International GmbH develops, manufactures, and markets generic pharmaceutical products. The company offers oral solids, gels, patch technologies, inhalers, anti-infective medicines, antibiotics, cardiovascular medicines, treatments for central nervous system disorders, gastrointestinal medicines, and oncology and respiratory therapies; medications for blood and blood forming organ disorders; and injectables including liquid vials, lyophilized vials, powder for oral suspensions, and pre-filled syringes. It also offers biopharmaceuticals such as biosimilars; oncology injectables; pharmaceutical intermediates, active pharmaceutical ingredients, and finished dosage forms; medicines for va...
Key Executives for Sandoz International GmbH
Head of North American Operations and President of Sandoz US
Head of Legal and General Counsel
Head of Western Europe, Middle-East & Africa
Compensation as of Fiscal Year 2014.
Sandoz International GmbH Key Developments
BioQuiddity Incorporated Signs Licensing Agreement with Sandoz International GmbH
May 14 15
BioQuiddity Incorporated has signed an exclusive licensing and supply agreement with Sandoz International GmbH under which Sandoz has the right to market BioQuiddity's ready-to-use ropivacaine and propofol infusion pharmaceutical products in the US. Under the agreement, BioQuiddity is responsible for obtaining the requisite regulatory approvals and supplying the unit-dose infusion systems, and Sandoz is responsible for marketing and commercializing the products.
Sandoz International Gmbh Launches New Inhaler for Asthma and COPD in Portugal and Ireland
Mar 18 15
Sandoz International GmbH has launched AirFluSal Forspiro, a new inhaler for patients with asthma and/or chronic obstructive pulmonary disease, or COPD, in Portugal and Ireland. AirFluSal offers the proven combination of salmeterol and fluticasone propionate in an innovative new device. It was developed at Aeropharm GmbH in Rudolstadt, Germany, Sandoz's global respiratory Center of Excellence.
Sandoz Announces US Market Introduction of Tobramycin Inhalation Solution, USP, Generic Version of TOBI
Jul 14 14
Sandoz announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation 1. Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa. Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 worldwide) have cystic fibrosis2. Sandoz is marketing tobramycin inhalation solution, USP in 300 mg/5 mL single-dose ampules, the same size and strength that is currently marketed by the brand.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|